Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Glucocorticoids and calcineurin inhibitors
5 evidence topics · 4 sources
Immunosuppression in primary and secondary FSGS: KDIGO 2021 glomerular diseases guideline
Treatment resistance in genetic forms of FSGS: KDIGO 2021 glomerular diseases guideline
Response to cyclosporine or mycophenolate mofetil with dexamethasone by APOL1 genotype: FSGS Clinical Trial
“The FSGS Clinical Trial involved 138 children and young adults who were randomized to cyclosporin or mycophenolate mofetil plus pulse oral dexamethasone with a primary outcome of proteinuria remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“APOL1 risk genotype did not affect response to either treatment regimen. Individuals with the risk genotype were more likely to progress to ESRD (P<0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At present, however, there are no data that would indicate that aggressive treatment with available agents retards progressive kidney function loss in these high-risk individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limits of glucocorticoids and calcineurin inhibitors in FSGS: review of burden
“Until recently, no medicines had been approved by the FDA or European Medicines Agency, with management focused on supportive care and proteinuria reduction.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Available treatments, such as glucocorticoids or calcineurin inhibitors, are limited in efficacy and safety.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote